NCT00242736CompletedPhase 4
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 350
- Locations
- 25
- Primary Endpoint
- The outcome variable will be the percentage of patients with heartburn resolution stratified by the presence or absence of EE
Study Overview
Brief Summary
The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with esomeprazole (NEXIUM®) in those subjects with Erosive Esophagitis (EE) and those without EE.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Symptoms of GERD as defined in this protocol: Heartburn (severity of mild, moderate or severe) 2 or more times in the 7 days prior to the Screening visit (Visit 1) and, on average, at least 2 times per week over the past 3 months.
- •Male or female, 18 to 70 years old, inclusive.
- •Non-pregnant, non-lactating female patients. Female patients must be postmenopausal, surgically sterile, or using a medically acceptable form of birth control, as determined by the investigator. Females of childbearing potential must agree to continue using an acceptable form of birth control throughout the conduct of the study.
- •Negative urine pregnancy test for females of childbearing potential.
- •Willingness to adhere to all protocol requirements.
Exclusion Criteria
- •Previous enrollment in the present study.
- •Significant clinical illness within 2 weeks prior to the first dose of study medication or a significant illness during the study.
- •Use of a PPI, including PRILOSEC OTC®, within 21 days of Screening (Visit 1) or at anytime during the study (Visit 1 through Visit 4).
- •Daily therapy with an H2 RA within 14 days of Screening (Visit 1): eg, ranitidine (ZANTAC®), cimetidine (TAGAMET®), nizatidine (AXID®), famotidine (PEPCID®) (occasional use; ie, less than daily, is permitted).
- •Use of H2 RAs at any frequency are prohibited throughout the entire study (Visit 1 through Visit 4).
- •A history of gastric or esophageal surgery (including, but not limited to, Nissen fundoplication and bariatric surgery), except for simple closure of a perforated ulcer or procedures that would not affect the study as determined by the Clinical Study Team physician at AstraZeneca.
- •Clinically significant gastrointestinal (GI) bleeding (eg, melena, frank hematochezia) within 3 days of Screening (Visit 1) or noted at the time of baseline EGD.
- •Non-acid related etiologies of esophagitis (eg, pill-induced, caustic ingestion or eosinophilic esophagitis).
- •Generalized bleeding disorders resulting from hemorrhagic diathesis (such as abnormalities in clotting factors or platelets).
Outcomes
Primary Outcomes
The outcome variable will be the percentage of patients with heartburn resolution stratified by the presence or absence of EE
Secondary Outcomes
- The outcome variables will be resolution of acid regurgitation, dysphagia, and epigastric pain symptoms after 2 and 4 weeks of treatment.
- The outcome variable will be the resolution of heartburn after 2 weeks of treatment.
- The outcome variables will be the presence or absence of EE at baseline and the resolution of heartburn at the end of the 4-week treatment period.
- The outcome variable used for this objective will be the percentage of endoscoped patients with EE (LA Classification Grades A-D) at baseline.
- Safety variables that will be measured and tabulated include adverse events, laboratory evaluations, physical exams, and vital signs.
Investigators
Study Sites (25)
Loading locations...
Similar Trials
Completed
Phase 1
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic ImpairmentHepatic ImpairmentNCT01271387Vanda Pharmaceuticals29
Completed
Phase 1
Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal FunctionRenal ImpairmentNCT01526746Vanda Pharmaceuticals32
Completed
Phase 1
Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy SubjectsHealthy VolunteersNCT01477619Vanda Pharmaceuticals60
Completed
Not Applicable
Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Gabapentin From Nerpentin 600 mg (Test ) F.C.T (Aman Pharma ,Egypt.) and Gabapentin From Neurontin 300 mg (Referance ) H.G.C. ( Pfizer Egypt)HealthyNCT04805827Pharma Guide CRO34
Completed
Phase 2
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in AdolescentsGastroesophageal Reflux DiseaseNCT01642602Takeda104